NCT01245439View on ClinicalTrials.gov

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions

Trial Locations (17)

16059

Bursa

20020

Denizli

23119

Elâzığ

27310

Gaziantep

34000

Istanbul

35100

Izmir

35170

Izmir

41380

İzmit

42080

Konya

45200

Manisa

54100

Izmir

55139

Samsun

58140

Sivas

01330

Adana

06100

Ankara

06500

Ankara

09100

Aydin

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01245439 - A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter